卡维地洛与琥珀酸美托洛尔治疗慢性收缩性心力衰竭的临床观察

目的： 分析卡维地洛与琥珀酸美托洛尔治疗慢性收缩性心力衰竭的临床疗效。方法： 选取于2009年1月-2011年1月在某院心内科接受治疗的慢性收缩性心力衰竭患者，随机分为A组和B组，其中A组应用卡维地洛进行治疗，B组应用琥珀酸美托洛尔进行治疗。待治疗24个月后随访两组患者的临床治疗效果、综合超声心动图主要指标、NT-proBNP的差异。结果： 共纳入267例收缩性心力衰竭患者，分析结果显示A组和B组治疗后左室射血分数、左室舒张末期内径及NT-proBNP明显改善，具有统计学意义（P<0.01）；与B组相比，A组对左心室射血分数的改善更加显著（P<0.05），而对左室舒张末期内径和NT-proBNP的改善两组无统计学差异（P>0.05）。结论： 卡维地洛和琥珀酸美托洛尔均可明显改善慢性收缩性心力衰竭患者的心功能指标；与琥珀酸美托洛尔相比，卡维地洛能更显著提高慢性收缩性心力衰竭患者的左室射血分数。

Clinical observation of carvedilol and metoprolol succinate in treatment against chronic congestive heart failure

OBJECTIVE To explore clinical curative effects of carvedilol and metoprolol succinate against chronic congestive heart failure (CHF).METHODS Patients with CHF hospitalized in Department of Cardiology, Henan Provincial People's Hospital, were randomly divided into two groups (Group A and Group B). Patients in Group A were treated with carvedilol, and Patients in Group B were treated with metoprolol succinate. After 24 months, difference of clinical curative effects, main index of combined echocardiography and NT-proBNP were analyzed between two groups.RESULTS A total of 267 CHF patients were enrolled into this study. After 24 months, left ventricular ejection fraction, left ventricular end diastolic diameter and NT-proBNP were obviously improved in both groups (P<0.01). Compared with Group B, improvement of left ventricular ejection fraction in Group A was more significant (P<0.05). But improvement of left ventricular end diastolic diameter and NT-proBNP showed no significant differences between two groups (P>0.05).CONCLUSION Carvedilol and metoprolol succinate both can improve cardiac function index in patients with CHF. But carvedilol improves left ventricular ejection fraction better than metoprolol succinate.